Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, whether the National Institute for Health and Care Excellence's recommendation of relugolix-estradiol-norethisterone for routine NHS use to treat endometriosis will extend to Northern Ireland.

The National Institute for Health and Care Excellence (NICE) makes recommendations on whether new medicines should be routinely funded by the National Health Service in England. NICE published final draft guidance on 13 March 2025 that recommends relugolix-estadiol-norethisterone as an option for treating symptoms of endometriosis in adults of reproductive age who have had medical or surgical treatment for endometriosis. NICE currently expects to publish final guidance in April 2025. Health is a devolved matter and decisions on the availability of medicines in Northern Ireland are a matter for the Northern Ireland Executive. Further information is available at the following link:

https://www.health-ni.gov.uk/topics/national-institute-health-and-care-excellence-nice